Additional information
| Trade Name | Palbace |
|---|---|
| Generic Name | Palbociclib |
| Manufacturer | Pfizer |
| Drug Type | Oncology |
| Indication | Breast Cancer |
| Doasage Form | Capsules |
| Packaging | 3 X 7 capsules |
| Strength | 75mg, 100mg, 125mg |
PALBACE (Palbociclib)
₹1.00 – ₹3.00
Palbociclib is classified as a “cyclin-dependent kinase (CDK) 4/6 inhibitor”. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone-positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
It is used for treating certain kinds of breast cancer in women past menopause.
- in a combination with Letrozole for the treatment of postmenopausal women with estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
- for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer in the combination with fulvestrant in women with disease progression following endocrine therapy.
Strengths available: 75mg, 100mg & 125mg
